Home > A. Molecular pathology > Targeted therapy > Therapeutical antibodies > vedolizumab
vedolizumab
Wednesday 1 June 2016
Entyvio
| WP |
Vedolizumab binds to integrin α4β7 (LPAM-1, lymphocyte Peyer’s patch adhesion molecule 1). Blocking the α4β7 integrin results in gut-selective anti-inflammatory activity.
Vedolizumab (trade name Entyvio) is a monoclonal antibody developed by Millennium Pharmaceuticals, Inc (a subsidiary of Takeda Pharmaceuticals) for the treatment of ulcerative colitis and Crohn disease .
See also
integrin α4β7 (LPAM-1, lymphocyte Peyer’s patch adhesion molecule 1)
